Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Increased serological, cancer-associated protein biomarker levels at diagnosis of large bowel adenoma: Risk of subsequent primary malignancy?

Research output: Contribution to journalJournal articleResearchpeer-review

  1. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Publishing your trial protocols with Acta Oncologica; your contribution to scientific transparency

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. European cancer rehabilitation and survivorship, 2018: one of a kind

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Open ventral hernia repair with a composite ventral patch - final results of a multicenter prospective study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Large Incisional Hernias Increase in Size

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Genome-wide cell-free DNA fragmentation in patients with cancer

    Research output: Contribution to journalLetterResearchpeer-review

View graph of relations

BACKGROUND: Blood-based, cancer-associated biomarkers may detect subjects at risk of having neoplastic diseases. The aim of the present study was to evaluate whether elevated serological protein biomarker levels may identify adenoma patients, who are at increased risk of being diagnosed with subsequent primary malignancy.

METHODS: Levels of CEA, CA19-9, TIMP-1 and YKL-40 were determined in blood samples collected prior to diagnostic bowel endoscopy due to symptoms of colorectal neoplasia. Follow-up time was ten years, and identified adenoma patients, who were diagnosed with subsequent primary intra- or extra-colonic malignant diseases. The biomarker levels were also determined in 400 subjects, who underwent diagnostic colonoscopy, had clean colorectum and were without apparent co-morbidity; these levels were used as reference levels. In the present study, biomarkers were interpreted as elevated when levels were above the reference intervals adjusting for age and gender. The 1-year and 5-years cumulative incidences were calculated.

RESULTS: Primary malignancies were identified in 175 (19%) of the 923 subjects diagnosed with adenomas at the primary bowel endoscopy. In detail, 20 of the 175 subjects were diagnosed with colorectal cancer (CRC) and 155 subjects with extra-colonic cancers. Thirty patients were diagnosed with malignancy within the first year. Three groups were established: 0: no elevated biomarkers; 1: 1 of the 4 biomarkers elevated; and 2: ≥2 biomarkers elevated. The cumulative 5-years incidence of malignancy was: 0: 6.9%; 1: 11.8%; and 2: 17.5% (p = .0009).

CONCLUSION: Elevated blood-based, cancer-associated protein biomarker levels in subjects diagnosed with adenomas at large bowel endoscopy identifies subjects at increased risk of being diagnosed with subsequent primary malignancy.

Original languageEnglish
JournalActa Oncologica
Volume58
Issue numbersup1: Advanced Adenomas of the Colon and Rectum
Pages (from-to)S42-S48
Number of pages7
ISSN0284-186X
DOIs
Publication statusPublished - 2019

ID: 55881402